Intellia Therapeutics (NTLA) EV/EBITDA: History & Chart

Intellia Therapeutics, Inc.(NTLA)

Biotechnology · Cambridge, MA

$12.28+0.16 (+1.28%)

Delayed quote: Oct 2, 2026, 3:40 PM EDT

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Cambridge, MA

377 employees

www.intelliatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Leonard

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Intellia Therapeutics, Inc. (NTLA)	$1.72B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.73B	4.45x	6.97x	36.61x	27.69x
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.14B	N/A	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$1.00B	12.42x	29.31x	194.51x	194.51x
Beam Therapeutics Inc. (BEAM)vs ›	$2.51B	N/A	N/A	N/A	N/A
TransMedics Group, Inc. (TMDX)vs ›	$2.74B	26.55x	36.07x	85.76x	85.76x
NeoGenomics, Inc. (NEO)vs ›	$472.39M	N/A	74.72x	37.71x	26.88x
NRC Health (NRC)vs ›	$459.30M	23.37x	16.26x	15.04x	16.68x
Shoulder Innovations, Inc. (SI)vs ›	$397.55M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$41.03M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Intellia Therapeutics, Inc. (NTLA)

$1.72B

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.73B

4.45x

6.97x

36.61x